DocWire News Editors

DocwireNews

According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) led to significant and clinically meaningful improvement in event-free survival (EFS) compared with second-line standard of care in patients with relapsed or refractory large B-cell lymphoma (LBCL). The findings were presented by Frederick L. Locke, MD, of Moffit Cancer Center in Tampa, Florida, as a plenary abstract at the 2021 American Society of Hematology Annual Meeting.&ldquo;The results of ZUMA-7 herald a paradigm shift in how we treat large B-cell lymphoma,&rdquo; said Dr. Locke. The improvement in EFS &ldquo;is remarkable and indicates that patients with lymphoma not responding to initial treatment or relapsing within 12 months should have the opportunity to get this therapy.&rdquo;At a median follow-up of 24.9 months, axi-cel significantly improved EFS (hazard ratio [HR] = 0.398; p &lt; 0.0001), with a median EFS that was more than four times longer than EFS with standard-of-care chemoimmunotherapy (8.3 vs. 2.0 months). The 24-month EFS was more than twice as long (41% vs. 16%).In addition to the improvements in EFS, overall response rates (ORR) and complete response rates (CRR) were significantly higher with axi-cel compared with standard of care. ORR was 83% with axi-cel compared with 50% with standard of care (odds ratio [OR] = 5.31; p &lt; 0.0001). The CRR was more than twice as high with axi-cel (65% vs. 32%).Median overall survival was evaluated as a preplanned interim analysis. Overall survival favored axi-cel, but it did not meet statistical significance (not reached vs. 35.1 months; HR = 0.730; p = 0.027). The researchers noted that, among patients assigned to the standard-of-care arm, 56% received commercially available or investigational CAR T-cell therapy off-protocol as a subsequent therapy.The safety of axi-cel was manageable and consistent with third-line use, according to Dr. Locke. Most patients in both arms experienced treatment-emergent grade &ge;3 adverse events (AEs). In the axi-cel arm, grade &ge;3 cytokine release syndrome (CRS) occurred in 6% of patients, while grade &ge;3 neurologic events occurred in 21% of patients. No grade 5 CRS or neurological events occurred. &ldquo;For both study arms, the rates and types of adverse events were consistent with expectations based on previous trials and real-world experience,&rdquo; Dr. Locke noted.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Axi-Cel Provides Durable Benefits Versus Standard of Care in Aggressive B-Cell Lymphoma

ASH Annual Meeting and Exposition 2021

According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) led to significant and clinically meaningful ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe